DK1384710T3 - Syntese af heterocykliske forbindelser indeholdende fem- eller seks-leddede ringe - Google Patents

Syntese af heterocykliske forbindelser indeholdende fem- eller seks-leddede ringe

Info

Publication number
DK1384710T3
DK1384710T3 DK03010988T DK03010988T DK1384710T3 DK 1384710 T3 DK1384710 T3 DK 1384710T3 DK 03010988 T DK03010988 T DK 03010988T DK 03010988 T DK03010988 T DK 03010988T DK 1384710 T3 DK1384710 T3 DK 1384710T3
Authority
DK
Denmark
Prior art keywords
nitrogen
halo
carbon
och2
excess
Prior art date
Application number
DK03010988T
Other languages
Danish (da)
English (en)
Inventor
Andrew V Schally
Nagy Attila
Zhi Cai Ren
Original Assignee
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24247176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1384710(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Tulane filed Critical Univ Tulane
Application granted granted Critical
Publication of DK1384710T3 publication Critical patent/DK1384710T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK03010988T 1995-11-27 1996-11-14 Syntese af heterocykliske forbindelser indeholdende fem- eller seks-leddede ringe DK1384710T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/562,652 US5843903A (en) 1995-11-27 1995-11-27 Targeted cytotoxic anthracycline analogs
PCT/EP1996/005029 WO1997019954A1 (en) 1995-11-27 1996-11-14 Targeted cytotoxic anthracycline analogs

Publications (1)

Publication Number Publication Date
DK1384710T3 true DK1384710T3 (da) 2008-11-17

Family

ID=24247176

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03010988T DK1384710T3 (da) 1995-11-27 1996-11-14 Syntese af heterocykliske forbindelser indeholdende fem- eller seks-leddede ringe
DK96938216T DK0863917T3 (da) 1995-11-27 1996-11-14 Målrettede cytotoksiske anthracyclin-analoger

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK96938216T DK0863917T3 (da) 1995-11-27 1996-11-14 Målrettede cytotoksiske anthracyclin-analoger

Country Status (27)

Country Link
US (2) US5843903A (2)
EP (2) EP0863917B1 (2)
JP (2) JP3987575B2 (2)
KR (2) KR100467899B1 (2)
CN (2) CN1166597C (2)
AT (2) ATE401305T1 (2)
AU (1) AU709539B2 (2)
BR (1) BR9611647B1 (2)
CA (2) CA2238574C (2)
CZ (1) CZ297297B6 (2)
DE (2) DE69630233T2 (2)
DK (2) DK1384710T3 (2)
EA (1) EA001372B1 (2)
ES (2) ES2310222T3 (2)
HK (1) HK1052920B (2)
HU (1) HU229870B1 (2)
IL (3) IL119691A (2)
IS (2) IS2178B (2)
MX (1) MX9804119A (2)
NO (2) NO324035B1 (2)
NZ (1) NZ322054A (2)
PL (3) PL191781B1 (2)
PT (2) PT863917E (2)
SK (2) SK284672B6 (2)
UA (1) UA67722C2 (2)
WO (1) WO1997019954A1 (2)
ZA (1) ZA969709B (2)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576239B1 (en) 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
AU766489B2 (en) 1998-11-13 2003-10-16 Cyclacel Limited Transport vectors
FR2786397B1 (fr) * 1998-11-30 2003-01-10 Synt Em Vecteurs peptidiques de substances a travers la barriere hematoencephalique pour etre utilises dans le diagnostic ou la therapie d'une affection du snc
FR2786398B1 (fr) * 1998-11-30 2002-12-27 Synt Em Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6528481B1 (en) 1999-02-16 2003-03-04 The Burnam Institute NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
US6380161B1 (en) 1999-06-21 2002-04-30 Inkine Pharmaceutical Company, Inc. Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions
CA2388844A1 (en) * 1999-11-12 2001-05-25 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
NZ522200A (en) * 2000-04-26 2004-07-30 Biosynthema Inc RGD (ARG-GLY-ASP) coupled to (neuro)peptides
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
KR100420007B1 (ko) * 2001-04-25 2004-03-02 노영쇠 안트라사이클린 유도체 및 이를 포함하는 항암제
CN1589151A (zh) 2001-09-21 2005-03-02 图兰恩教育基金管理人 诊断或治疗性促生长素抑制素或铃蟾肽类似物的连接物及其用途
EP1531846A4 (en) * 2002-02-27 2006-04-19 Us Gov Health & Human Serv Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
US7771727B2 (en) 2002-03-01 2010-08-10 The Administrators Of The Tulane Educational Fund Conjugates of therapeutic or cytotoxic agents and biologically active peptides
US7544767B2 (en) 2002-04-05 2009-06-09 Burnham Institute For Medical Research HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
EP1506786B1 (en) * 2002-05-21 2016-11-23 Daiichi Sankyo Company, Limited Medicinal compositions containing ghrelin
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
CN101134119A (zh) 2002-05-24 2008-03-05 血管技术国际股份公司 用于涂覆医用植入物的组合物和方法
EP1542739B1 (en) 2002-09-26 2008-12-10 Angiotech International Ag Perivascular wraps
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
US20050043215A1 (en) 2003-02-19 2005-02-24 Tamara Minko Complex drug delivery composition and method for treating cancer
AU2007221964B2 (en) * 2003-04-22 2008-12-11 Ipsen Pharma S.A.S. Peptide vectors
CN101791409A (zh) * 2003-04-22 2010-08-04 研究及应用科学协会股份有限公司 肽载体
US7097993B2 (en) 2003-06-25 2006-08-29 Wisconsin Alumni Research Foundation Method for identifying an agent that modulates type 1 phosphatidylinositol phosphate kinase isoform β661 activity
WO2005086951A2 (en) * 2004-03-10 2005-09-22 Threshold Pharmaceuticals, Inc. Hypoxia-activated anti-cancer agents
US20070060534A1 (en) * 2005-06-30 2007-03-15 Threshold Pharmaceuticals, Inc. Anthracycline analogs
JP5340155B2 (ja) * 2006-09-06 2013-11-13 エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング 細胞結合分子を有するジソラゾールのコンジュゲート及びそれらの誘導体、新規ジソラゾール誘導体、それらの製法ならびに使用
EP1900742A1 (en) 2006-09-07 2008-03-19 AEterna Zentaris GmbH Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
US20100087370A1 (en) * 2007-02-14 2010-04-08 The General Hospital Corporation Modulation of nitric oxide signaling to normalize tumor vasculature
RU2377247C2 (ru) * 2007-12-27 2009-12-27 Федеральное государственное образовательное учреждение высшего профессионального образования Санкт-Петербургский государственный университет Молекулярный конъюгат на основе синтетических аналогов люлиберина и его применение в качестве средства доставки днк в клетки гормон-чувствительных опухолей (варианты)
EP2240495B1 (en) 2008-02-01 2015-07-15 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
CA2721140C (en) * 2008-04-11 2016-02-09 Tianjin Hemay Bio-Tech Co. Ltd. Tetracyclic anthraquinone antibiotic derivatives with high activity, process for preparing the same and use thereof
KR101328315B1 (ko) * 2008-04-11 2013-11-11 티안진 헤메이 바이오-텍 컴퍼니 리미티드 고활성의 안트라사이클린 항생물질 유도체, 이의 제조방법 및 사용
AU2009270988A1 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
JP5584236B2 (ja) 2009-02-20 2014-09-03 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ 神経ペプチドｙ受容体結合化合物を有する細胞毒性コンジュゲート
CN102050856B (zh) * 2009-11-03 2014-04-30 天津和美生物技术有限公司 具有高活性的表阿霉素的衍生物及其制备和应用
KR101897307B1 (ko) 2010-12-02 2018-09-10 네르비아노 메디칼 사이언시스 에스.알.엘. 모르폴리닐 안트라사이클린 유도체의 제조 방법
CN105198966B (zh) * 2014-06-26 2019-06-21 中国人民解放军军事医学科学院毒物药物研究所 GnRH类似物-细胞毒分子缀合物、其制备方法及用途
MX379365B (es) 2014-06-30 2025-03-11 Tarveda Therapeutics Inc Conjugados y partículas direccionados y formulaciones de estos.
EP3045540A1 (en) 2015-01-19 2016-07-20 Æterna Zentaris GmbH Enzymatic process for the regioselective manufacturing of N-Fmoc-doxorubicin-14-O-dicarboxylic acid mono esters
US11160871B2 (en) 2015-10-28 2021-11-02 Tarveda Therapeutics, Inc. SSTR-targeted conjugates and particles and formulations thereof
US10450340B2 (en) 2017-02-16 2019-10-22 Monopar Therapeutics Inc. 3′-deamino-3′-(2″-pyrroline-1″-yl)-5-imino-13-deoxyanthracyclines and methods of preparation
WO2021068051A1 (en) * 2018-11-13 2021-04-15 Provincial Health Services Authority Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
AU2023239751A1 (en) 2022-03-25 2024-09-05 Provincial Health Services Authority Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725350A (en) * 1972-04-26 1973-04-03 Commercial Soluents Corp Polymeric substances comprising the reaction product of melamine, aldehyde and oxazolidines
US4299822A (en) * 1980-06-09 1981-11-10 Sidney Farber Cancer Institute, Inc. N-Trifluoroacetyladriamycin-14-O-hemiglutarate and -hemiadipate and therapeutic compositions containing same
US4464529A (en) * 1982-07-20 1984-08-07 Sri International Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin
IL106992A (en) * 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US5217955A (en) * 1989-09-15 1993-06-08 Biomeasure, Inc. Treatment of cancer with peptide analog of bombesin, grp, litorin or neuromedin
DK0434960T3 (da) * 1989-12-19 1996-10-14 Pharmacia Spa Chirale 1,5-diiod-2-methoxy- eller benzyloxymellemprodukter
US5304687A (en) * 1989-12-19 1994-04-19 Farmitalia Carlo Erba S.R.L. Morpholinyl derivatives of doxorubicin and process for their preparation
DK0450461T3 (da) * 1990-04-06 1995-10-23 Univ Tulane LHRH-analoger
DK0450480T3 (da) * 1990-04-06 1995-08-14 Univ Tulane Somatostatinaloger
JP3169425B2 (ja) * 1992-03-27 2001-05-28 三共株式会社 アジドペンタンサイクリトール
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates

Also Published As

Publication number Publication date
EA199800492A1 (ru) 1998-12-24
BR9611647A (pt) 1999-02-23
CA2471775C (en) 2008-01-29
US5843903A (en) 1998-12-01
ZA969709B (en) 1997-08-25
PT863917E (pt) 2004-02-27
CA2238574A1 (en) 1997-06-05
EA001372B1 (ru) 2001-02-26
NO20051111L (no) 2005-03-01
ATE401305T1 (de) 2008-08-15
KR100445754B1 (ko) 2004-12-08
NO982252L (no) 1998-05-15
EP1384710B1 (en) 2008-07-16
SK284392B6 (sk) 2005-03-04
EP0863917A1 (en) 1998-09-16
IL134685A (en) 2002-12-01
DE69637604D1 (de) 2008-08-28
PL187230B1 (pl) 2004-06-30
JP2007045845A (ja) 2007-02-22
IS2178B (is) 2006-12-15
HK1017363A1 (en) 1999-11-19
CA2238574C (en) 2004-10-19
PL191781B1 (pl) 2006-07-31
CA2471775A1 (en) 1997-06-05
WO1997019954A1 (en) 1997-06-05
DK0863917T3 (da) 2004-01-19
IL134685A0 (en) 2001-04-30
ES2310222T3 (es) 2009-01-01
PL326865A1 (en) 1998-10-26
JP2000502055A (ja) 2000-02-22
DE69630233D1 (de) 2003-11-06
HK1052920B (zh) 2005-03-04
HUP9903771A3 (en) 2000-07-28
AU709539B2 (en) 1999-09-02
KR19990071672A (ko) 1999-09-27
PT1384710E (pt) 2008-10-08
NO982252D0 (no) 1998-05-15
EP1384710A1 (en) 2004-01-28
IL119691A0 (en) 1997-02-18
CZ297297B6 (cs) 2006-11-15
CN1137136C (zh) 2004-02-04
IL119691A (en) 2002-02-10
IS2634B (is) 2010-06-15
IS4734A (is) 1998-05-05
KR20040037176A (ko) 2004-05-04
US6184374B1 (en) 2001-02-06
ES2205067T3 (es) 2004-05-01
HU229870B1 (en) 2014-10-28
CN1166597C (zh) 2004-09-15
CN1202903A (zh) 1998-12-23
ATE251179T1 (de) 2003-10-15
CZ135798A3 (cs) 1998-10-14
CN1405127A (zh) 2003-03-26
PL188786B1 (pl) 2005-04-29
HUP9903771A2 (hu) 2000-02-28
HK1052920A1 (en) 2003-10-03
BR9611647B1 (pt) 2010-03-09
SK284672B6 (sk) 2005-08-04
JP4778405B2 (ja) 2011-09-21
NO324035B1 (no) 2007-07-30
SK62898A3 (en) 1999-06-11
JP3987575B2 (ja) 2007-10-10
EP0863917B1 (en) 2003-10-01
KR100467899B1 (ko) 2005-01-24
MX9804119A (es) 1998-09-30
UA67722C2 (en) 2004-07-15
NZ322054A (en) 1999-04-29
DE69630233T2 (de) 2004-08-05
IS8567A (is) 2006-11-09
AU7572296A (en) 1997-06-19

Similar Documents

Publication Publication Date Title
DK1384710T3 (da) Syntese af heterocykliske forbindelser indeholdende fem- eller seks-leddede ringe
SE9301911D0 (sv) New peptide derivatives
DK0932597T3 (da) Anvendelse af gamma-hydroxysmørsyreamider til behandling af lægemiddelafhængighed og især alkoholisme
DE3566251D1 (en) Novel intermediate and method for its preparation
BR9813835A (pt) Composto, composição farmacêutica e método de tratamento ou prevenção de uma desordem tromboembólica
ES8603408A1 (es) Un procedimiento para la preparacion de un compuesto de 2-oxindol-1-carboxamida
MXPA06001274A (es) Compuestos novedosos que poseen actividad inhibitoria contra transporador dependiente de sodio.
HU9600963D0 (en) Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
DE69511260D1 (en) Bicyclische amidinderivate als no-synthetase inhibitoren
HRP20000585B1 (en) Substituted bisindolymaleimides for the inhibition of cell proliferation
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
MY108849A (en) Novel compound
EA199900684A1 (ru) Производные иминоазаантрациклинона для лечения амилоидоза
ATE218861T1 (de) Vasculäre hypertrophicsuppressor
ATE228359T1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
DK316986A (da) Kemiske forbindelser, som er phosphodiesterase type iii inhibitorer
ES8302703A1 (es) "un procedimiento para la preparacion de fenil-quinolicidinas".
PT81422A (en) Process for the preparation of 3-amino-2,3-dihidro-1-benzoxepincompounds
YU58300A (sh) Postupak za dobijanje 3-aminoalkohola
GEP19981168B (en) Benzimidazole derivatives and pharmaceutically acceptable salts thereof, intermediate compounds, method of their reception, stable crystals, a composition for inhibition of angiotensin ii